More precisely, AML patients receiving VEN-AZA, might harbor FLT3-ITD mutation at diagnosis, or may develop the same mutation at relapse, demonstrating secondary or acquired VEN resistance during the course of the disease (68). This evidence concerns the gene FLT3 and acute myeloid leukemia.